文献速递泌尿生殖与妇科肿瘤放疗

选择性盆腔淋巴结照射联合同步大分割前列腺推量治疗高危局限期前列腺癌的长期结果

Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localized high risk prostate cancer: Long term results from a prospective clinical trial.
PubMed 文献 · Radiother Oncol · 2021-07-26

这项前瞻性单臂研究纳入230例高危前列腺癌患者,接受盆腔淋巴结45 Gy/25次、前列腺同步推量22.5 Gy(总67.5 Gy/25次)及2–3年ADT。中位随访11.2年,10年生化失败累积发生率33.4%、远处转移16.5%、总生存76.3%,≥3级晚期胃肠和泌尿毒性分别为2.3%和7.5%。

要点

  • 10年生化失败33.4%、远处转移16.5%、总生存76.3%。
  • PSA nadir ≥0.05 ng/mL与生化失败和远处转移显著相关。
  • ≥3级晚期胃肠和泌尿毒性5年累积发生率分别为2.3%和7.5%。

核心结论

  • 选择性盆腔淋巴结照射联合同步大分割前列腺推量及长期ADT治疗高危前列腺癌,可获得可接受的10年生化控制和生存,且≥3级毒性低。

研究设计与样本

  • 前瞻性单臂研究,纳入230例高危前列腺癌患者(cT3、PSA >20 ng/mL或Gleason评分8–10)。

主要发现

  • 中位随访11.2年(IQR 8.1–12.9),10年生化失败累积发生率33.4%、远处转移16.5%、总生存76.3%。
  • 多因素分析显示PSA nadir ≥0.05 ng/mL与生化失败(HR 6.8,95% CI 4–11.8,p < 0.001)和远处转移(HR 7.5,95% CI 3.9–14.5,p < 0.0001)相关。
  • PSA nadir ≥0.1 ng/mL(HR 5.2,95% CI 2.2–12,p = 0.0001)和ADT使用≤12个月(对比>24个月)(HR 2.3,95% CI 1.3–3.9,p = 0.004)与更差生存相关。
  • 任何≥3级晚期胃肠和泌尿毒性5年累积发生率分别为2.3%和7.5%。

关键数值与推荐

  • 放疗方案:盆腔淋巴结和前列腺45 Gy/25次,前列腺同步推量22.5 Gy,总剂量67.5 Gy/25次。
  • ADT疗程2–3年。
  • 主要终点为生化失败,次要终点包括远处转移和总生存。
  • 晚期毒性采用CTCAE v3.0评估。

临床怎么用

  • 该方案可作为高危局限期前列腺癌的放疗选择之一,需结合长期ADT。
  • PSA nadir ≥0.05 ng/mL提示生化失败和远处转移风险增高,应加强随访。
  • ADT使用≤12个月与更差生存相关,支持足疗程ADT。

局限性

  • 单臂研究,无同期对照组。
  • 样本量230例,随访时间中位11.2年。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To report on long-term results of elective pelvic nodal irradiation (EPNI) and a simultaneous hypofractionated prostate boost for high-risk prostate cancer. MATERIALS AND METHODS: This was a prospective single-arm study. Patients with high-risk disease (cT3, PSA >20 ng/mL, or Gleason score 8-10) were eligible. Patients received 45 Gy in 25 fractions to the prostate and pelvic lymph nodes with a simultaneous intensity-modulated radiotherapy boost of 22.5 Gy to the prostate (total dose 67.5 Gy in 25 fractions), with androgen deprivation therapy (ADT) for 2-3 years. The primary endpoint was biochemical failure. Secondary endpoints included distant metastases and overall survival. Multivariable analysis was performed to look for predictive factors. Late toxicity was assessed using CTCAE v3.0. RESULTS: 230 patients enrolled. Median follow-up was 11.2 years (IQR 8.1-12.9). At 10 years, cumulative incidence of biochemical failure was 33.4%, distant metastasis was 16.5%, and overall survival was 76.3%. On multivariable analysis, PSA nadir ≥0.05 ng/mL was associated with biochemical failure (HR 6.8, 95% CI 4-11.8, p < 0.001) and distant metastases (HR 7.5, 95% CI 3.9-14.5, p < 0.0001). PSA nadir ≥0.1 ng/mL (HR 5.2, 95% 2.2-12, p = 0.0001) and ADT use ≤12 months (versus >24 months) (HR 2.3, 95% CI 1.3-3.9, p = 0.004) were associated with worse survival. The 5-year cumulative incidence of any late grade ≥3 gastrointestinal and genitourinary toxicity was 2.3% and 7.5%, respectively. CONCLUSION: EPNI and a simultaneous hypofractionated prostate boost combined with long-term ADT for high-risk prostate cancer resulted in acceptable 10-year biochemical control and survival with low grade ≥3 toxicity.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Glicksman RM, Loblaw A, Morton G, et al. Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localized high risk prostate cancer: Long term results from a prospective clinical trial. Radiother Oncol. 2021. PMID: 34324914. doi:10.1016/j.radonc.2021.07.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。